Quick Answer
Aardvark Therapeutics, Inc. reported Net Income of -$57.59 million for fiscal year 2025.
Aardvark Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$57.59M | -179.7% |
| 2024 | -$20.59M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$16.32M | -290.1% | -13.6% |
| June 30, 2025 | -$14.37M | -163.7% | -54.3% |
| March 31, 2025 | -$9.31M | -327.5% | -122.6% |
| September 30, 2024 | -$4.18M | — | +23.3% |
| June 30, 2024 | -$5.45M | — | -150.2% |
| March 31, 2024 | -$2.18M | — | — |
- Aardvark Therapeutics, Inc. showed a decrease of -179.7% in Net Income compared to the prior fiscal year.
- Over the 2024–2025 period, Aardvark Therapeutics, Inc.’s net income has declined by 179.7% (from -$20.59 million to -$57.59 million).
- The most recent figure is from Aardvark Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: